doxorubicin + thalidomide + dexamethasone

A combination regimen of **doxorubicin**, **thalidomide**, and **dexamethasone** is used as a multi-agent chemotherapy protocol, primarily for the treatment of **multiple myeloma**. Each component contributes a distinct mechanism: doxorubicin is an anthracycline antineoplastic antibiotic that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity; thalidomide is an immunomodulatory agent with anti-angiogenic and direct anti-myeloma effects; dexamethasone is a potent synthetic glucocorticoid that exerts anti-inflammatory and cytotoxic effects on lymphoid cells. Used together, these agents act synergistically to induce remission in patients with advanced or refractory multiple myeloma, though the combination increases the risk of hematologic and thromboembolic toxicities. Protocols and component dosing schemes vary, and this regimen may sometimes involve pegylated liposomal doxorubicin instead of conventional doxorubicin to improve tolerability. The combination is generally considered for patients not responding adequately to standard therapy or in salvage/induction settings[3][4].

Brand names

None specific to this combination as a single branded product

Other names

Thalidomide-doxorubicin-dexamethasoneDoxorubicin-dexamethasone-thalidomide